Centergate’s Subsidiary Shandong Huasu Receives NMPA Clinical Trial Approval for BDB Tablets – Novel Combination Antihypertensive Enters Clinical Development

Beijing Centergate Technologies (Holdings) Co., Ltd. (SHE: 000931) announced that its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has received a Clinical Trial Approval Notification from China's National Medical Products Administration…

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.